Theravance Biopharma (TBPH) EBT Margin (2013 - 2026)
Theravance Biopharma (TBPH) reported EBT Margin of 36.56% for Q1 2026, up 5532.0% year-over-year from 0.65% in Q1 2025, and up 74.13% quarter-over-quarter from 141.29% in Q4 2025.
Theravance Biopharma (TBPH) EBT Margin (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of EBT Margin data on file, last reported at 36.56% in Q1 2026.
- EBT Margin for Q1 2026 came in at 36.56%, up 5532.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 32.09% (up 3473.0% YoY), and the FY2025 annual result was 278.09%, up 27497.0% from the prior year.
- EBT Margin grew to 36.56% in Q1 2026 per TBPH's latest filing, from 141.29% in the prior quarter.
- Over five years, EBT Margin peaked at 279.47% in Q2 2025 and troughed at 1589.4% in Q1 2022.
- A 5-year average of 144.67% and a median of 91.88% in 2025 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2023: EBT Margin plunged 103212 bps in 2022, then surged 137357 bps in 2023.
- A 5-year view of EBT Margin shows it stood at 97.34% in 2022, then surged by 71 bps to 28.56% in 2023, then surged by 804 bps to 200.97% in 2024, then slumped by 170 bps to 141.29% in 2025, then surged by 74 bps to 36.56% in 2026.
- Business Quant data shows TBPH's EBT Margin at 36.56% in Q1 2026, 141.29% in Q4 2025, and 14.45% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | -36.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.56% |
| Dec 31, 2025 | -141.29% |
| Sep 30, 2025 | -14.45% |
| Jun 30, 2025 | 279.47% |
| Mar 31, 2025 | -91.88% |
| Dec 31, 2024 | 200.97% |
| Sep 30, 2024 | -59.59% |
| Jun 30, 2024 | -106.77% |
| Mar 31, 2024 | -71.72% |
| Dec 31, 2023 | -28.56% |
| Sep 30, 2023 | -48.32% |
| Jun 30, 2023 | -103.19% |
| Mar 31, 2023 | -215.83% |
| Dec 31, 2022 | -97.34% |
| Sep 30, 2022 | -128.69% |
| Jun 30, 2022 | -206.32% |
| Mar 31, 2022 | -1,589.40% |
| Dec 31, 2021 | -387.84% |
| Sep 30, 2021 | -423.81% |
| Jun 30, 2021 | -407.50% |